Objective To assess the efficacy and safety of levoamlodipine besylate for essential hypertension. Methods We searched MEDLINE (1999 to October 2007), EMBASE (1999 to October 2007), The Cochrane Library (Issue 3, 2007), CNKI (1999 to 2007), Wanfang (1999 to 2007), VIP (1999 to 2007) and CBM (1999 to October 2007). The quality of included studies was critically evaluated. Data analyses were performed with The Cochrane Collaboration’ s RevMan 4.2 software. Results A total of 345 articles were retrieved, but only 17 were finally included. Meta-analyses showed that the effective rate in patients receiving levoamlodipine besylate was significantly higher than that in patients receiving indapamide (RD 0.14, 95%CI 0.06 to 0.22, P=0.0004), while no significant differences were noted between the levoamlodipine besylate group and other control groups. The incidence of adverse effects was significantly lower in the levoamlodipine besylate group compared to the indapamide group (RD –0.12, 95%CI –0.21 to –0.03, P=0.01), the amlodipine group (RD –0.06, 95%CI –0.11 to –0.01, P=0.02) and the nitrendipine group (RD –0.27, 95%CI –0.46 to – 0.08, P=0.006). No significant differences were observed between the levoamlodipine besylate group and other control groups. Conclusion Levoamlodipine besylate tends to have better efficacy and safety profiles compared with other antihypertensive drugs. However, most trials included in the review were of poor quality and, so, multi-center large-scale randomized controlled trials of higher quality are needed to confirm this.
目的:观察辛伐他汀、吡格列酮和苯磺酸左旋氨氯地平联合治疗代谢综合征疗效。方法:76例初诊代谢综合征患者,服用吡格列酮15mg/d、苯磺酸左旋氨氯地平25mg/d、辛伐他汀10mg/d,疗程1个月。观察治疗前后血压、腰围、体重指数、血糖、血胰岛素、血尿酸和血脂水平等变化。结果:患者治疗后血糖、血脂、胰岛素水平、血压均明显降低,差别有统计学意义(Plt;001)。腰围、体重指数略有下降,无统计学意义,血尿酸变化不明显。结论:吡格列酮、辛伐他汀和苯磺酸左旋氨氯地平联合治疗代谢综合征能够改善胰岛素抵抗和代谢异常,疗效可靠、服药简单、依从性好,效价比合理,无不良反应。